I am interested in how skin cancer (melanoma) evolved specific mechanisms to repair its DNA, rendering it notoriously resistant to radiotherapy. I am focusing on the melanoma-specific protein called MITF and its new role in the regulation of DNA repair pathways. My further aim is to identify a new vulnerability we could take advantage of in personalised melanoma therapies.
I did my Master’s degree and PhD in Grenoble, France where I studied the mechanisms of cellular aging in mammalian cells. My work was published in Cancer Research in 2009.
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert K. et al, (2019), Genes Dev, 33, 310 - 332
Sumoylation of ING2 regulates the transcription mediated by Sin3A
Ythier D. et al, (2010), Oncogene, 29, 5946 - 5956
Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma
Ythier D. et al, (2010), Lung Cancer, 69, 180 - 186
WNT16B, a new biomarker of senescent cells in vitro and in vivo, is necessary for the p53-dependent activation of p21WAF1 in cellular senescence
Binet R. et al, (2010), BULLETIN DU CANCER, 97, S67 - S67
WNT16B Is a New Marker of Cellular Senescence That Regulates p53 Activity and the Phosphoinositide 3-Kinase/AKT Pathway
Binet R. et al, (2009), Cancer Research, 69, 9183 - 9191